The most encouraging findings have emerged from the CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study, NCT01327846), which illustrated that administration of canakinumab, an IL-1β inhibitor, resulted in a dose-dependent decline in hospitalizations due to heart failure, along with a reduction in a composite endpoint of heart failure hospitalizations and mortality related to heart failure [43]. This evidence concerns the gene IL1B and heart failure.